| Oct 9 |
FibroGen Inc (FGEN) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Shifts
|
| Sep 16 |
Duchenne muscular dystrophy: major trials and events to watch in 2023
|
| Sep 6 |
FibroGen CFO, CMO to leave company by year's end
|
| Sep 3 |
FibroGen to Present at the H.C. Wainwright 26th Annual Global Investment Conference
|
| Aug 9 |
FibroGen, Inc. (FGEN) Q2 2024 Earnings Call Transcript
|
| Aug 9 |
FibroGen, Inc. (NASDAQ:FGEN) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
|
| Aug 6 |
FibroGen (FGEN) Reports Q2 Loss, Tops Revenue Estimates
|
| Aug 6 |
FibroGen: Q2 Earnings Snapshot
|
| Aug 6 |
FibroGen GAAP EPS of -$0.16 beats by $0.20, revenue of $50.64M beats by $15.98M
|
| Aug 6 |
FibroGen Reports Second Quarter 2024 Financial Results and Provides Business Update
|
